<DOC>
	<DOC>NCT01393899</DOC>
	<brief_summary>This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease who completed the double-blind induction treatment in Study A3921083 and achieved clinical response-100 and/or clinical remission (CDAI&lt;150) at Week 8.</brief_summary>
	<brief_title>The Safety And Efficacy Of Maintenance Therapy With CP-690,550</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subjects who met study entry criteria, and who completed Week 8 visit of Induction Study A3921083. Subjects who achieve clinical response100 (reduction in CDAI by 100 points) and/or clinical remission (CDAI&lt;150) in Study A3921083. Women of childbearing potential must test negative for pregnancy prior to study enrolment. Subjects who had major protocol violation (as determined by the Sponsor) in the A3921083 study. Subjects likely to require any type of surgery during the study period. Fecal culture/toxin assay indicating presence of pathogenic infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>tofacitinib</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>CP-690,550</keyword>
	<keyword>maintenance therapy</keyword>
</DOC>